<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9707">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05691972</url>
  </required_header>
  <id_info>
    <org_study_id>43USTH2201</org_study_id>
    <nct_id>NCT05691972</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing</brief_title>
  <official_title>A Randomized, No-treatment-controlled, Evaluator-blinded, Multi-center Study to Evaluate the Effectiveness and Safety of Restylane Contour in the Treatment of Temple Hollowing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, no-treatment-controlled, evaluator-blinded, multi-center study to&#xD;
      evaluate the effectiveness and safety of Restylane® Contour in correction of temple&#xD;
      hollowing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate based on the Blinded Evaluators' live assessment of the GTVDS</measure>
    <time_frame>Baseline to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rates, as assessed by the Blinded Evaluator at 6, 9 and 12 months after baseline for the treatment group</measure>
    <time_frame>6,9,12 months after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Temporal Hollowing</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Contour</intervention_name>
    <description>a sterile, biodegradable, transparent gel of nonanimal cross-linked HA (20 mg/mL) with the addition of lidocaine hydrochloride (3 mg/mL)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant, non-breastfeeding females, 22 years of age or older&#xD;
&#xD;
          -  Intent to undergo treatment for correction of temple hollowing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel&#xD;
             or to gram positive bacterial proteins&#xD;
&#xD;
          -  Known/previous allergy or hypersensitivity to local anesthetics, e.g., lidocaine or&#xD;
             other amide-type anesthetics or nerve blocking agents (if intended to be used for that&#xD;
             subject)&#xD;
&#xD;
          -  Previous facial surgery (e.g., facelift) above the level of the horizontal line from&#xD;
             subnasale that in the Treating Investigator´s opinion could interfere with the study&#xD;
             safety and/or effectiveness assessments&#xD;
&#xD;
          -  Any previous aesthetic procedures or implants&#xD;
&#xD;
          -  Recurrent temporal headaches such as temporal tendinitis migraine. Have a history of&#xD;
             migraines or frequent headaches, as determined by the (Treating) Investigator, that&#xD;
             could interfere with the study safety and/or effectiveness assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Galderma R&amp;D</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>817-961-5000</phone>
    <email>aestheticclinicaltrials@galderma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Solana Beach</city>
        <state>California</state>
        <zip>92075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Adventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galderma Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galderma R Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>April 21, 2023</last_update_submitted>
  <last_update_submitted_qc>April 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

